

Rec'd PET/PTO 1 6 JUN 2005  
10/539674

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	PCT/US03/40763
	<b>Filing Date</b>	18 December 2003
	<b>First Named Inventor</b>	Jack Dale LEBER
	<b>Title</b>	PEPTIDE DEFORMYLASE INHIBITORS
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	P51402

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. **20462**

Or

☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ The address associated with Customer Number **20462**

Or

☐ Firm or Individual Name:

Address:	
Address:	
City:	State: Zip:
Country:	
Telephone:	Fax:


I am the:

☐ Applicant/Inventor:

☒ Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature: 	Date: <u>June 14, 2005</u>
Name: <b>Stephen Venetianer</b>	Telephone: 610-270-5040
Title and Company: <b>Vice President, Pharmaceuticals, SmithKline Beecham Corporation</b>	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>STATEMENT UNDER 37 CRF 3.73(b)</b>	
<b>Applicant/Patent Owner: SMITHKLINE BEECHAM CORPORATION</b> <b>Application No./Patent No.: PCT/US03/40763 Filed/Issue Date: 18 December 2003</b> <b>Entitled: PEPTIDE DEFORMYLASE INHIBITORS</b>	
<b>SMITHKLINE BEECHAM CORPORATION, a corporation, states that it is:</b>	
1. <input checked="" type="checkbox"/> the assignee of the entire right, title, and interest; or 2. <input type="checkbox"/> an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either;	
A. <input type="checkbox"/> An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached. OR B. <input type="checkbox"/> A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
1. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
2. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
3. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
<input type="checkbox"/> Additional documents in the chain of title are listed on a supplemental sheet.	
<input checked="" type="checkbox"/> Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
<div style="text-align: center;">   _____  Signature </div>	<div style="text-align: center;">   _____  Date </div>
<div style="text-align: center;"> STEPHEN VENETIANER  _____  Printed or Typed Name </div>	<div style="text-align: center;"> 610-270-5040  _____  Telephone Number </div>
<div style="text-align: center;"> Vice President, Pharmaceuticals  _____  Title </div>	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Box No. VIII(iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America).** The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII(I) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

**Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))**

**for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. PCT/ (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications: (prior to priority).....

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Name: LEBER, Jack Dale

PA

Residence: 1250 Collegeville Road, Collegeville, Pennsylvania 19426, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Jack Dale Leber  
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: Dec. 8, 2003  
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

2-00 Name: LI, Mei

PA

Residence: 1250 Collegeville Road, Collegeville, Pennsylvania 19426, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Citizenship: People's Republic of China

Inventor's Signature: Mei Li  
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: Dec. 8, 2003  
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☒ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iv)".

**Continuation of Box No. VIII(i) to (v) Declaration**

*If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.*

300 Name: LEE, Jinhwa

PA

Residence: 1250 Collegeville Road, Collegeville, Pennsylvania 19426, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Citizenship: South Korea

Inventor's Signature: [Signature]

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: Dec. 8, 2003

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

400 Name: AUBART, Kelly M.

PA

Residence: 1250 Collegeville Road, Collegeville, Pennsylvania 19426, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Kelly Aubart

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 12/13/03

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

500 Name: CHRISTENSEN, Siegfried B., IV

PA

Residence: 1250 Collegeville Road, Collegeville, Pennsylvania 19426, United States of America

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Siegfried B. Christensen

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: December 8, 2003

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)